• Takeda takes step towards EU Entyvio extension biospectrumasia
    April 03, 2019
    European Medicines Agency accepts Takeda’s Marketing Authorization Application for a subcutaneous formulation of Vedolizumab for maintenance therapy in moderately to severely active Ulcerative Colitis and Crohn’s Disease
PharmaSources Customer Service